Loss to Follow-Up in Patients With Proliferative Diabetic Retinopathy or Diabetic Macular Edema DOI Creative Commons
Ryan S. Huang, Sumana C. Naidu, Andrew Mihalache

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(12), P. e2450942 - e2450942

Published: Dec. 13, 2024

Importance Effective management of proliferative diabetic retinopathy (PDR) and macular edema (DME) requires reliable patient follow-up to prevent disease progression. Objective To investigate the sociodemographic clinical factors associated with being lost (LTFU) among individuals PDR or DME treated anti–vascular endothelial growth factor (VEGF) intravitreal injections (IVIs) panretinal photocoagulation (PRP). Design, Setting, Participants This cohort study included a multicenter, retrospective review patients in Toronto, Canada, from January 1, 2012, December 31, 2021. Data were analyzed February 1 May 2024. Exposures All received at least anti-VEGF IVI PRP session. Main Outcomes Measures The primary outcome was LTFU rate, defined as absence an ophthalmic visit intervention 1-year period following individual’s last treating retinal specialist. Univariable multivariable logistic regression models conducted evaluate associations between rate. Results Overall, 2961 (mean [SD] age, 71 [13] years; 1640 [55.4%] male) included, whom 507 (17.1%) over mean (SD) 61 (22) months. In analysis, older (age ≥85 years vs age <65 years: odds ratio [OR], 0.58; 95% CI, 0.40-0.81; P = .002), those worse baseline visual acuity (>20/200 Snellen 20/40 better: OR, 0.68; 0.48-0.97; .04), (OR no DME, 0.60; 0.43-0.83; .003), frequent clinic visits (≥6 <6 visits: 0.78; 0.62-0.98; high burden first year low burden, 0.40; 0.21-0.76; .006) less likely be LTFU. contrast, males females, 1.23; 1.04-1.52; living further point care (>200 ≤20 km 2.65; 1.85-3.76; < .001), IVIs, 2.10; 1.24-3.55; .001) more Compared White patients, Black (OR, 1.50-2.95; Hispanic 1.54; 1.05-2.21; .03) Conclusions Relevance found multiple rates. Identifying higher risk developing targeted strategies may reduce progression vision loss PDR.

Language: Английский

Loss to Follow-Up in Patients With Proliferative Diabetic Retinopathy or Diabetic Macular Edema DOI Creative Commons
Ryan S. Huang, Sumana C. Naidu, Andrew Mihalache

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(12), P. e2450942 - e2450942

Published: Dec. 13, 2024

Importance Effective management of proliferative diabetic retinopathy (PDR) and macular edema (DME) requires reliable patient follow-up to prevent disease progression. Objective To investigate the sociodemographic clinical factors associated with being lost (LTFU) among individuals PDR or DME treated anti–vascular endothelial growth factor (VEGF) intravitreal injections (IVIs) panretinal photocoagulation (PRP). Design, Setting, Participants This cohort study included a multicenter, retrospective review patients in Toronto, Canada, from January 1, 2012, December 31, 2021. Data were analyzed February 1 May 2024. Exposures All received at least anti-VEGF IVI PRP session. Main Outcomes Measures The primary outcome was LTFU rate, defined as absence an ophthalmic visit intervention 1-year period following individual’s last treating retinal specialist. Univariable multivariable logistic regression models conducted evaluate associations between rate. Results Overall, 2961 (mean [SD] age, 71 [13] years; 1640 [55.4%] male) included, whom 507 (17.1%) over mean (SD) 61 (22) months. In analysis, older (age ≥85 years vs age <65 years: odds ratio [OR], 0.58; 95% CI, 0.40-0.81; P = .002), those worse baseline visual acuity (>20/200 Snellen 20/40 better: OR, 0.68; 0.48-0.97; .04), (OR no DME, 0.60; 0.43-0.83; .003), frequent clinic visits (≥6 <6 visits: 0.78; 0.62-0.98; high burden first year low burden, 0.40; 0.21-0.76; .006) less likely be LTFU. contrast, males females, 1.23; 1.04-1.52; living further point care (>200 ≤20 km 2.65; 1.85-3.76; < .001), IVIs, 2.10; 1.24-3.55; .001) more Compared White patients, Black (OR, 1.50-2.95; Hispanic 1.54; 1.05-2.21; .03) Conclusions Relevance found multiple rates. Identifying higher risk developing targeted strategies may reduce progression vision loss PDR.

Language: Английский

Citations

2